153 results about "Vaccine strain" patented technology

The invention discloses a toxoplasma gondii attenuated vaccine strain RH delta rop67 as well as a construction method and application thereof, and belongs to the technical field of parasitic disease prevention and control and biological product preparation. The attenuated vaccine strain is constructed by performing targeted knockout on the ROP67 gene in a toxoplasma gondii strain RH delta ku80 through a CRISPR / Cas9 mediated gene editing technology. Compared with a wild type strain, the attenuated vaccine strain shows remarkable attenuation characteristic and good immunogenicity. A test result shows that the attenuated vaccine strain can induce a host to generate specific immune response mainly based on cellular immunity, maintains a protection effect on toxoplasma gondii infection in a relatively long immune period, and has a protection effect on tachyzoite infection and a chronic infection stage of toxoplasma gondii strains with different virulence; the survival ability of a host to tachyzoite infection can be improved, and the formation level of cysts in tissues is reduced. The invention provides a technical scheme with long-term immune potential for research and development of toxoplasma gondii attenuated vaccines.

The invention discloses a Newcastle disease vaccine strain with high antibody escape ability and a modification method thereof, the cell strain is preserved in China General Microbiological Culture Collection Center on January 19, 2024, the address of the preservation unit is CGMCC No.45870, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the classification name of the strain is Newcastle disease virus strain. The recombinant NDV vaccine strain has the same antigen site as the current NDV gene VII type epidemic strain and has the efficient proliferation efficiency superior to that of a classical vaccine strain La Sota, the thermal stability of the NDV vaccine strain is improved by the constructed recombinant vaccine strain, and the cost of vaccine cold-chain transportation is reduced.

The invention provides a nucleic acid probe, a primer group, a kit, a detection method and application, and relates to the technical field of biology. The nucleotide sequence of the nucleic acid probe is as shown in SEQ ID NO. 1; wherein the 3'end of the nucleic acid probe is modified with MGB, and locked nucleic acid is modified at a base position corresponding to the difference between the swine fever wild strain and the swine fever vaccine strain in the nucleotide sequence. According to the nucleic acid probe, a specific sequence is utilized to precisely target a swine fever wild strain, and locked nucleic acid modification is introduced at a differential site, so that the recognition capability on single-base mismatch is remarkably enhanced, non-specific binding to a vaccine strain is thoroughly blocked, and false positive interference is eliminated; and 3 '-terminal MGB modification is matched to improve the binding stability and sensitivity, so that the efficient and accurate identification of the swine fever wild strain under the immune background is ensured.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention belongs to the technical field of virus detection, and discloses a digital PCR (polymerase chain reaction) kit for simultaneously detecting African swine fever virus, porcine reproductive and respiratory syndrome virus and swine fever virus, and the kit comprises primers and probes as shown in SEQ ID NO.1-SEQ ID NO.24. After a single system of an African swine fever virus-VP72 gene, an African swine fever virus-CD2V gene, an African swine fever virus-14L gene, a porcine reproductive and respiratory syndrome virus-RdRP gene, a porcine reproductive and respiratory syndrome virus-European strain, a porcine reproductive and respiratory syndrome virus-American strain, a swine fever virus-vaccine strain and a swine fever virus-wild strain is tested, a nine-fold digital PCR system containing an internal standard is established; through tests of indexes such as linearity, specificity, minimum detection limit, repeatability, comparison of a single digital PCR system and a multiple digital PCR system, the currently developed digital PCR multiple detection kit completely meets development requirements and is high in specificity and sensitivity, and the minimum detection limit of the digital PCR multiple detection kit can reach 10 Copies / mu L or below.

A nanobody classical swine fever virus (CSFV)-E0-Nb1 against a CSFV E0 protein, and an encoding gene and use thereof are provided, belonging to the technical field of biological detection. The nanobody CSFV-E0-Nb1 has an amino acid sequence shown in SEQ ID NO: 1 and can be expressed using an expression system. The nanobody is coupled with a quantum dot to obtain an immunochromatographic test strip for distinguishing antibodies against a CSFV E2 subunit vaccine strain from those of a wild strain infected on site, and there is a simple production process of the test strip. The immunochromatographic test strip can differentiate and diagnose the antibodies against the CSFV E2 subunit vaccine strain and the wild strain, and has the advantages of rapid, convenient, and instant detection, thus providing a new method for the detection of classical swine fever (CSF) purification.

The invention discloses a construction method and application of a toxoplasma gondii polygene deletion vaccine strain. According to the invention, a TgBFD1 gene and a TgDAHPS gene are respectively knocked out from an ME49 [delta] 6pgdh1 insect strain through a gene editing technology, and a polygene deleted insect strain [delta] 6pgdh1 [delta] bfd1 [delta] dahps is successfully constructed; the strain can be subcultured in vitro, has the characteristics of no toxicity and no formation of tissue cysts in a host body, has better immune protection after immunization and inoculation, and can resist lethal infection of highly toxic strains. The toxoplasma gondii polygene deletion strain provided by the invention has better safety than ME49 delta 6pgdh1 strain, the toxicity of the toxoplasma gondii polygene deletion strain is obviously reduced, tissue cysts are not formed, the toxoplasma gondii polygene deletion strain can effectively resist infection of wild poisonous strains, the toxoplasma gondii polygene deletion strain has good immune protection capability, the defects that ME49 delta 6pgdh1 still has toxicity and can form tissue cysts are overcome, and the toxoplasma gondii polygene deletion strain has good application prospects. A method is provided for developing a safe and efficient toxoplasma gondii vaccine.

The invention discloses a dual fluorescent quantitative PCR (polymerase chain reaction) primer probe combination for identifying a PRV (pseudorabies virus) vaccine strain and a wild strain. The dual fluorescent quantitative PCR primer probe combination comprises two pairs of primers gB-F and gB-R, gE-F and gE-R, and probes gB-probe and gE-probe, wherein the two pairs of primers are used for specifically amplifying a PRV gB gene and a PRV gE gene; through existence of real-time fluorescence PCR amplification curves of the PRV gB gene and the gE gene, a PRV vaccine strain (gE gene deletion) and a wild strain can be rapidly, specifically, sensitively and stably identified, technical support can be provided for porcine pseudorabies epidemic disease monitoring, and thorough purification of the PRV in a live pig breeding link is facilitated.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody combination for detecting the N protein of porcine reproductive and respiratory syndrome virus (PRRSV) and its application. The combination consists of monoclonal antibodies 1D7 and 5C7. Sequence analysis has clarified the CDR amino acid sequences of the heavy and light chain variable regions, as shown in SEQ ID NO.1-SEQ ID NO.12, and a double-antibody sandwich ELISA detection method has been established based on this. This method uses 1D7 as the coating antibody and 5C7 as the labeling antibody, achieving a sensitivity of up to 100 pg / mL, high specificity, no cross-reactivity with irrelevant antigens such as PEDV, and effectively detecting the N protein in PRRSV vaccine strains such as JXA1-R and R-98. This invention can be used for rapid detection of PRRSV antigen in clinical samples and for vaccine quality control.

The invention belongs to the field of biology, and discloses an mRNA (messenger ribonucleic acid) with a nucleotide sequence as shown in SEQ ID NO.3. Antiserum of a strain (A / chick / Gansuu / 28 / 2024) corresponding to the mRNA has relatively good reactivity with other strains and poorer reaction with a current vaccine strain RE-13, the branched strain is a current epidemic strain, and the mRNA prepared from the HA gene of the strain has the advantage of strong protection; the invention also aims to provide the mRNA, application thereof and a vaccine.

The invention relates to a primer-probe set, comprising a forward primer having the nucleotide sequence of SEQ ID NO:1 and a reverse primer having the nucleotide sequence of SEQ ID NO:2, and a peptide nucleic acid (PNA) probe having the sequence of HEX-OO-(SEQ ID NO:3)-Lysine-BHQ1, which are used for differentiating the Peste des Petits Ruminants (PPR) virus vaccine and field strains and for preventing false positive results arising from the PPR vaccine, as well as to their operating temperatures. Said primer-probe set can differentiate between the vaccine strain containing the nucleotide sequence of SEQ ID NO:4 and the field strain containing the nucleotide sequence of SEQ ID NO:5. Thus, by means of said primer-probe set, false positive results arising from the PPR vaccine are prevented, and accordingly, unnecessary quarantine measures are also avoided.

This invention discloses a candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine, its construction method, and its application. The candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine is *R. anatipestifer* strain CH-1. B739_RS01935-B739_RS07625 A candidate attenuated live vaccine strain with double gene deletion, deposited at the China Center for Type Culture Collection (CCTCC) on May 22, 2025, with accession number CCTCC NO: M20251080, at Wuhan University, Wuhan, China, has been deposited on that date. The attenuated live strain constructed in this invention showed no significant impact on the weight gain of ducklings after immunization, demonstrating good safety. Furthermore, the protection rate against challenge with the wild-type virulent RACH-1 strain reached 83.3% after immunization, indicating excellent immunoprotective efficacy.

The invention relates to the technical field of rotaviruses, in particular to a G8P [8] type group A rotavirus CZ-23 and application thereof. The invention relates to a G8P [8] type group A rotavirus CZ-23, which is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 11, 2023, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation number is CGMCC (China General Microbiological Culture Collection Center) The invention provides a novel human rotavirus wild strain which is reported and separated for the first time in China, and the strain is strong in virus replication capability and good in hereditary stability, can be applied to development of vaccine strains of human rotavirus vaccines, and is suitable for attenuated rotavirus oral vaccines.

This invention relates to the field of molecular biology detection technology, specifically disclosing a quadruple fluorescent PCR primer-probe combination, reaction system, and detection method for identifying wild-type and vaccine strains of Mycoplasma gallisepticum. The quadruple fluorescent PCR primer-probe combination for identifying wild-type and vaccine strains of Mycoplasma gallisepticum includes a universal primer-probe set for detecting Mycoplasma gallisepticum and specific primer-probe sets targeting three vaccine strains, F-36, TS-11, and 6 / 85, respectively. The quadruple fluorescent PCR primer-probe combination, reaction system, and method of this invention for identifying wild-type and vaccine strains of Mycoplasma gallisepticum can simultaneously detect and differentiate the DNA of wild-type Mycoplasma gallisepticum and its three different vaccine strains (F-36, TS-11, and 6 / 85), making detection and differential diagnosis more efficient, economical, and convenient; it has advantages such as high sensitivity, good specificity, rapid high throughput, and simple operation.

The invention belongs to the technical field of animal epidemic disease pathogen detection, and particularly relates to a primer composition and a kit for identifying a Brucella universal type and a vaccine strain, the primer composition comprises primer pairs and probes for identifying the Brucella universal type, a pig breed S2 vaccine strain and a cattle breed A19 vaccine strain; the primer pair for identifying the universal type of Brucella is shown as SEQ ID NO.1-2, and the probe is shown as SEQ ID NO.3; a primer pair for identifying the pig breed S2 vaccine strain is SEQ ID NO.4-5, and a probe is SEQ ID NO.6; the primer pair for identifying the bovine species A19 vaccine strain is SEQ ID NO.7-8, and the probe is SEQ ID NO.9; the specificity and the sensitivity are good.

The application discloses a Toxoplasma gondii DAHPS gene deletion vaccine strain and application thereof. The application provides a Toxoplasma gondii gene knockout strain, which is obtained by directly knocking out a 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase TgDAHPS gene of the Toxoplasma gondii through a gene editing technology, the gene ID of the TgDAHPS gene is TGGT1_221260, and the nucleotide sequence is shown as SEQ ID NO. 1. The gene deletion strain Δdahps provided by the application can grow normally in vitro, does not reproduce in a host in vivo, and is almost non-toxic. After immunization of the Δdahps strain, the host can be induced to have good immune protection. The Δdahps has the advantages of weak virulence and almost no reproduction in vivo as the attenuated vaccine strain of the Toxoplasma gondii, can improve the resistance of the host to wild Toxoplasma gondii, and can be used for preventing the infection of the Toxoplasma gondii in humans and animals, and has important significance for developing more Toxoplasma gondii vaccines.

The invention relates to the technical field of virus detection, in particular to a fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection probe 1106VP and / or 1106WP and primers 1106VWF and 1106VWR. The invention also discloses a fluorescent RT-PCR detection reagent, a fluorescent RT-PCR detection kit, a fluorescent RT-PCR detection probe, a primer, the fluorescent RT-PCR detection reagent and the application of the fluorescent RT-PCR detection kit in identification of a porcine reproductive and respiratory syndrome NJ-1106R strain and a porcine reproductive and respiratory syndrome non-NJ-1106R strain. The probe and the primer disclosed by the invention are high in specificity and high in sensitivity; the accuracy is high, and the accuracy rate of blind sample detection is 100%; the kit is high in universality, can be used for detecting virus liquid for cell culture in a laboratory, and can also be used for detecting porcine serum and tissue samples in clinical samples. The method is an effective method for identifying the PRRSV NJ-1106R vaccine strain and other PRRSV wild strains.

The invention discloses a toxoplasma gondii double-gene deletion attenuated vaccine strain as well as a construction method and application thereof. The toxoplasma gondii double-gene deletion attenuated vaccine strain is constructed by deleting a ku80 gene and a CDC14 gene on the basis of a toxoplasma gondii type II PLK strain, and is named as PLK [delta] TgKu80 [delta] TgCDC14 ([delta] CDC14 for short), and experimental results show that the pathogenicity of the strain is remarkably reduced after the CDC14 gene is knocked out. In order to further explore the immune protection effect on toxoplasma gondii acute infection mice, secondary acute infection is carried out on mice immunized with delta CDC14 strains, and the result shows that compared with non-immunized group mice, no immunized mice die within 30 days, and all non-immunized mice die within 13 days. Therefore, the double-gene deletion attenuated vaccine strain has the potential of being used as a vaccine, and an effective technical means is provided for preventing toxoplasma gondii infection.

This invention relates to the field of biotechnology, and aims to provide a monoclonal antibody 7A12 for identifying genotype 2 classical swine fever, along with its preparation and application methods. This monoclonal antibody contains an Ig domain V of the antibody heavy chain. H CDR1, V H CDR2 and V H CDR3, and the Ig domain V of the antibody light chain L CDR1, V L CDR2 and V L CDR3; wherein, the V H CDR1, V H CDR2 and V H The amino acid sequences of CDR3 are shown in SEQ ID NO:1-3, respectively; the V L CDR1, V L CDR2 and V L The amino acid sequences of CDR3 are shown in SEQ ID NO:4-6. The antibody provided by this invention has advantages such as high titer, strong specificity, and high affinity; it also has high sensitivity and specificity, and shows no cross-reactivity with type 1 classical swine fever vaccine strains. Serologically, it can differentiate and diagnose infection and vaccine immunization with genotype 2 classical swine fever wild-type strains. Furthermore, it can be used to develop a blocking ELISA kit for identifying genotype 2 classical swine fever, effectively diagnosing and purifying genotype 2 classical swine fever virus.

This invention provides a live attenuated Brucella vaccine strain M5Δ pyrE Its construction methods and applications belong to the field of biotechnology. The M5... pyrE The strain was obtained by knocking out Brucella mesenteriae strain M5. pyrE Genetically constructed and deposited at the China Center for Type Culture Collection. This invention discovers that... pyrE The gene is associated with Brucella virulence; knocking out this gene significantly weakens Brucella virulence and reduces its intracellular and mouse viability. Compared to the existing vaccine strain M5-9026, M5... pyrE The strain exhibits superior immunoprotective effects, effectively inducing humoral and Th1 cellular immune responses, and demonstrates good safety. The M5 strain constructed in this invention... pyrE This strain has promising potential as a candidate strain for a live attenuated vaccine to prevent brucellosis in animals.

The invention relates to a porcine reproductive and respiratory syndrome chimeric virus vaccine strain as well as a construction method and application thereof, and belongs to the technical field of biology. The porcine reproductive and respiratory syndrome chimeric virus provided by the invention is an RNA (Ribonucleic Acid) virus, and the nucleotide sequence of the RNA virus is SEQ ID NO: 1. The chimeric virus has better safety and effectiveness, can relieve lung injury caused by the porcine reproductive and respiratory syndrome virus and promote removal of viruses in piglets, can be used as a vaccine candidate strain of the porcine reproductive and respiratory syndrome virus, and is beneficial to prevention and control of the porcine reproductive and respiratory syndrome.

The application belongs to the field of vaccines and genetic engineering technology, and relates to an H3N2 canine influenza recombinant virus strain and application thereof. Specifically, the application relates to a recombinant canine influenza vaccine strain which is obtained by recombination of the following genes: an HA gene, an NA gene, a PB1 gene, a PB2 gene, a PA gene, an NP gene, an M gene and an NS gene; wherein the sequence of the HA gene is shown as SEQ ID NO:1; and / or the sequence of the NA gene is shown as SEQ ID NO:2. The application also relates to an H3N2 canine influenza recombinant vaccine and a method for preparing the H3N2 canine influenza recombinant vaccine.

The invention relates to the technical field of virus detection, and particularly discloses a fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection kit for identifying a classical swine fever virus vaccine strain and a wild strain. The kit comprises a specific primer combination, a specific fluorescent probe, a fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) reaction solution, a positive control and a negative control, the primer combination comprises a vaccine strain and wild strain specific primer pair targeting a virus 5 '-UTR region and an E2 gene; the fluorescent probes comprise probes corresponding to the targets respectively and are marked with fluorophores; verification is carried out through double gene targets, missing detection caused by single site mutation is effectively avoided, and the method has the advantages of high specificity, high sensitivity and high accuracy; the invention further provides a non-diagnostic purpose detection method of the kit, detection can be completed within 2 h, and the kit is suitable for rapid identification, epidemic situation monitoring and purification effect evaluation of classical swine fever virus vaccine strains and wild strains in clinical samples.

The invention provides a mycobacterium tuberculosis attenuated live vaccine strain solid culture medium as well as preparation and application thereof, and the raw material of the solid culture medium comprises supernate obtained by filtering potato water prepared from selenium-enriched yellow-core potatoes with the total selenium content of 15-150mu g / kg. A solid culture medium without animal-derived components is obtained; and the culture method is further optimized, so that the mycobacterium tuberculosis is high in thallus proliferation speed and not easy to be infected by infectious microbes when being cultured. The solid culture medium disclosed by the invention is simple in manufacturing process, low in implementation cost and high in conversion efficiency, and has a prominent popularization prospect.

This study describes the construction, identification, and application of a pseudorabies virus (PRV) triple-gene deletion vaccine strain (gI / gE / TK). Based on the JS-2012-ΔgI / gE double-gene deletion strain, the TK virulence gene was further deleted using CRISPR technology. Its pathogenicity was evaluated in KM mice and piglets, and its immunoprotective efficacy was verified in piglets. This provides theoretical support for the clinical prevention and control of pseudorabies; establishes experimental models in mice and pigs to study the immunoprotective efficacy of the triple-gene deletion strain; and prepares for the subsequent development and evaluation of vaccines using PRV strains as vectors.

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.

The present invention provides a recombinant attenuated respiratory syncytial virus (RSV) comprising F protein of stabilized pre-fusion RSV, or comprising protein consisting of the amino acid sequence represented by SEQ ID NO: 2 or functional fragment thereof, and provides genome of the recombinant RSV and a recombinant vector comprising the genome. The recombinant attenuated RSV can be provided as a live vaccine strain which maintains infectability and has excellent safety and stability.

The present invention discloses a monoclonal antibody 2D1B1 against canine distemper virus H protein and its application, belonging to the technical field of monoclonal antibodies. The present invention screened out 9 monoclonal antibodies by indirect ELISA and indirect immunofluorescence identification. After indirect immunofluorescence identification, the 9 monoclonal antibodies obtained were all able to react with the vaccine strain (CDV-Onderstepoort). The results of Western Blot tests showed that the 9 monoclonal antibodies screened out were all able to react specifically with the eukaryotic expressed CDV H protein, among which 2D1B1 was also able to react specifically with the prokaryotic expressed CDV H protein, that is, 2D1B1 was not only able to react with the attenuated vaccine strain and the virulent isolated strain, but also with both eukaryotic and prokaryotic expressed CDV H proteins, and at the same time had a high neutralizing potency (2 6 ), which can be used to prepare broad-spectrum detection reagents and therapeutic preparations for identifying canine distemper virus H protein.

This invention belongs to the field of bioengineering technology, specifically relating to the construction of a double-gene-deleted attenuated African swine fever virus strain and its application as a vaccine. This invention combines the deletion of the MGF505-7R and I267L genes in the ASFV CN / GS 2018 virus, reducing the virulence of the parent strain and obtaining an attenuated African swine fever vaccine strain. The attenuated African swine fever vaccine strain completely attenuates pigs after immunization, with 100% survival rate, and provides immune protection against challenge with the virulent ASFV CN / GS / 2018 strain. It can serve as a safe and effective candidate vaccine for the prevention and control of African swine fever, possessing significant social value.

The invention discloses establishment and application of a PCR (Polymerase Chain Reaction) detection method for detecting brucella S19, which is characterized in that a specific interval of a brucella S19 genome and a brucella A19 genome is analyzed by adopting high-throughput Mauve genome colinearity, and a specific primer is designed. The PCR detection primer of the Brucella S19 vaccine strain is screened out, and the PCR detection method for differential diagnosis of the Brucella S19 vaccine strain is established. The PCR method disclosed by the invention has the characteristics of clinical convenience and rapid diagnosis, can be widely used in clinical application of Brucella S19 differential diagnosis, and has better market prospect and economic value.